Javelin Pharmaceuticals, Inc. (AMEX: JAV - News) announced today it has accepted the resignation of Dr. Curtis Wright, its Executive Vice President for Risk Management and Regulatory Affairs, for personal reasons. Dr. Wright will pursue a business opportunity outside the field of pain drug development that offers him the opportunity to work closer to his home and continue as a consultant to Javelin.

Dr. Daniel Carr, Javelin’s Chief Executive Officer and Chief Medical Officer, stated, “Curt made a significant contribution to Javelin’s growth from a drug development company to a commercial pain treatment company. Curt’s primary career interest was in the field of addiction, and we wish him well as he returns to that career. The focus of his consultancy for Javelin will remain risk management and regulatory affairs, areas in which we now benefit from more mature, autonomous and greatly strengthened teams than when he first joined the Company. Pending identification of his successor, the directors in these areas will continue to advance our programs based upon our internal resources and our longstanding relationships with major advisory firms, with the benefit of Curt’s continued counsel as a consultant.”

“I continue to believe strongly in Javelin’s mission, product candidates, and success in the marketplace,” said Dr. Wright. “I look forward to my advisory role with Javelin’s capable risk management and regulatory teams.”

About Javelin Pharmaceuticals, Inc.

With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has three drug candidates in US Phase 3 clinical development. One of these US Phase 3 drug candidates, Dyloject(TM), has received Marketing Authorization Application (MAA) approval and favorable pricing in the UK, where it is now being sold. Previous clinical trials have demonstrated its safety and rapid onset of action. For additional information about Javelin, please visit the company's website at http://www.javelinpharmaceuticals.com.

Forward Looking Statement

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.